Hepatocellular carcinoma (HCC) is the most familiar primary hepatic malignancy with a poor
prognosis. The incidence of HCC and the associated deaths have risen in recent decades …

Hepatocellular carcinoma (HCC) remains a major global health burden, and sorafenib, a
multi-kinase inhibitor, has shown effectiveness in the treatment of HCC and is considered as …

Purpose Hepatocellular carcinoma (HCC) is a complicated disease with low survival rate
due to frequent recurrence and the lack of efficient therapies. For advanced HCC, sorafenib …

The multikinase inhibitor sorafenib is currently the treatment of reference for advanced
hepatocellular carcinoma (HCC). In our report, we examined the cytotoxic effects of …

Sorafenib is an important first-line treatment option for liver cancer due to its well-
characterized safety profile. While novel first-line drugs may have better efficacy than …

Sorafenib is the first-line therapeutic agent for hepatocellular carcinoma (HCC), but the drug
resistance has become a major impediment. Previously we found that the abnormal iron …

Cell death is a fundamental feature of multicellular organisms' development and a key driver
of degenerative diseases. Ferroptosis is a new regulatory cell death mediated by iron …

The most widespread type of liver cancer, HCC, is associated with disabled cellular death
pathways. Despite therapeutic advancements, resistance to current systemic treatments …

Simple Summary In recent decades, scientific discoveries brought up several new
treatments and improvements for patients suffering from hepatocellular carcinoma (HCC) …

Sorafenib is a potent inducer of ferroptosis used to manage hepatocellular carcinoma
(HCC). The ferroptosis induced by sorafenib activates the p62–Keap1–Nrf2 pathway …